Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats.

Journal of veterinary pharmacology and therapeutics·2026

Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.

Journal of veterinary pharmacology and therapeutics·2025

Same author

Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes.

Annals of hematology·2020

Same author

Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization.

Annals of hematology·2019

Same author

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2019

Search research articles

Related Experiment Video

Updated: Mar 23, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.

Jacqueline M Theodorou¹, Yogini Patel², Patricia Ford^3,4,5

¹1 Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA, USA.

Journal of Pharmacy Practice

|March 31, 2016

Summary

Limited data exist for rivaroxaban in cancer patients. Two cases of recurrent venous thromboembolism (VTE) occurred in cancer patients on rivaroxaban, highlighting the need for more research on its safety and efficacy in this population.

Keywords:

anticoagulation oncology

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Mar 23, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Venous thromboembolism (VTE) is a significant complication in cancer patients.
Low-molecular-weight heparin is the current guideline-recommended pharmacologic agent for VTE in this population.
Rivaroxaban, an oral factor Xa inhibitor, offers convenience but has limited study data in cancer patients.

Observation:

Two cases of active cancer patients experiencing recurrent VTE while on rivaroxaban therapy are presented.
Case 1: A 64-year-old female with recurrent pulmonary embolism.
Case 2: A 70-year-old female with recurrent deep vein thrombosis.

Findings:

Both patients experienced thromboembolic events despite receiving rivaroxaban.
These recurrences suggest potential limitations of rivaroxaban in managing VTE in certain cancer patients.

Implications:

Further clinical trials are essential to establish the safety and efficacy of rivaroxaban for VTE treatment and prevention in cancer patients.
Healthcare providers should exercise caution when prescribing rivaroxaban for VTE in this specific patient group.
More research is needed to identify optimal anticoagulation strategies for cancer-associated VTE.